Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
Yan L, Qu S, Shang J, Shi X, Kang L, Xu N, Zhu M, Zhou J, Jin S, Yao W, Yao Y, Chen G, Chang H, Zhu X, Yu L, Wu D, Fu C.
Yan L, et al. Among authors: zhou j.
Cancer Med. 2021 Jan;10(2):563-574. doi: 10.1002/cam4.3624. Epub 2020 Dec 23.
Cancer Med. 2021.
PMID: 33356013
Free PMC article.